Oncotarget

Case Reports:

ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma

Eric I. Marks, Sahithi Pamarthy, Don Dizon, Ari Birnbaum, Evgeny Yakirevich, Howard Safran and Benedito A. Carneiro _

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:245-251. https://doi.org/10.18632/oncotarget.26521

Metrics: PDF 783 views  |   Full Text 1019 views  |   ?  


Abstract

Eric I. Marks1,*, Sahithi Pamarthy2,*, Don Dizon1, Ari Birnbaum1, Evgeny Yakirevich3, Howard Safran1 and Benedito A. Carneiro1

1Division of Hematology-Oncology, Lifespan Cancer Institute, Warren-Alpert Medical School of Brown University, Providence, RI, USA

2Atrin Pharmaceuticals, Pennsylvania Biotechnology Center, Doylestown, PA, USA

3Department of Pathology, Lifespan Cancer Institute, Warren-Alpert Medical School of Brown University, Providence, RI, USA

*These authors contributed equally to this work

Correspondence to:

Benedito A. Carneiro, email: Benedito.carneiro@lifespan.org

Keywords: ROS1; GOPC; FIG; angiosarcoma; Targeted Therapy

Received: October 22, 2018     Accepted: December 12, 2018     Published: January 04, 2019

ABSTRACT

Hepatic angiosarcoma (HAS) is a rare and highly lethal malignancy with few effective systemic treatments. Relatively little is known about the genetic abnormalities that drive this disease. As a result, there has been minimal progress towards applying targeted therapies to the treatment of HAS. We describe the first reported case of a patient with HAS that harbored a fusion of ROS1 with GOPC/FIG. Similar to other rearrangements involving ROS1, the resulting fusion protein is believed to act as a major driver of carcinogenesis and may be subject to inhibition by drugs that target ROS1 such as crizotinib. We then queried the MSK-IMPACT clinical sequencing cohort and cBioportal datasets, demonstrating the previously unknown prevalence of ROS1-GOPC fusions in soft tissue sarcomas and hepatobiliary cancers. Amplification of these genes was also found to correlate with reduced overall survival. This is followed by a review of the role played by ROS1 rearrangements in cancer, as well as the evidence supporting the use of targeted therapies against the resulting fusion protein. We suggest that testing for ROS1 fusion and, if positive, treatment with a targeted therapy could be considered at the time of diagnosis for patients with angiosarcoma. This report also highlights the need for further investigation into the molecular pathophysiology of this deadly disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26521